Panacea Biotec's EmulsiPan Adjuvant Included in CEPI Library, Company to Foray into Commercialisation

Panacea Biotec's EmulsiPan adjuvant has been included in the CEPI (Coalition for Epidemic Preparedness Innovations) Library of adjuvants. This recognition highlights EmulsiPan's potential in enhancing the efficacy and dose-sparing effects of vaccines and biotherapeutics. EmulsiPan is an oil-in-water emulsion adjuvant, produced by nano-emulsification of squalene along with surfactants and buffers. It is a ready-to-use sterile emulsion, supplied in a 10 mL USP Type | glass vial for research purposes. The global market for adjuvants is expected to reach over $4.8 billion by 2028, and EmulsiPan's open access and affordability signal Panacea Biotec’s entry into commercialisation of adjuvants. EmulsiPan has been utilized in several high-impact preclinical studies and collaborative research programs, demonstrating its versatility and potential to enhance vaccine efficacy.